In a large multicentric study that included patients with de novo DLBCL who were treated with R-CHOP, it was confirmed that survivin was an independent predictive factor for poor outcomes in ABC-DLBCL, and the patients seemed to benefit less from this treatment and may require additional novel agents [26]. The gene discussed is BIRC5; the disease is diffuse large B-cell lymphoma.